| Ricardo Cruzado, | |
|
Ave. Luis Munos Marin, Caguas, PR 00725 | |
| (787) 653-3434 | |
| Not Available |
| Full Name | Ricardo Cruzado |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 21 Years |
| Location | Ave. Luis Munos Marin, Caguas, Puerto Rico |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881796290 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 13541 (Puerto Rico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Tampa | Tampa, FL | Hospital |
| Florida Hospital Carrollwood | Tampa, FL | Hospital |
| Adventhealth Dade City | Dade city, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sheridan Radiology Services Of West Florida Inc | 4082998075 | 82 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
Scientists at The Forsyth Institute have found that blue light can be used to selectively suppress certain bacteria commonly associated with destructive gum disease.
Individuals have a right to participate in risky research trials, which might harm their health or even kill them, and institutional review boards (known as research ethics committees in the UK) – which are responsible for deciding whether a particular research trial can take place in a given institution – are potentially impeding the progress of research by rejecting such studies on ethical grounds, according to a Viewpoint published in The Lancet today [Wednesday 18 September].
Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
A non-invasive fingertip test can identify coronary disease at its earliest stages and may provide an easy to use tool for daily clinical practice, according to a recent study published in the Journal of the American College of Cardiology.
› Verified 1 days ago
| Entity Name | Sheridan Radiology Services Of West Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235674904 PECOS PAC ID: 4082998075 Enrollment ID: O20170413000678 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
Scientists at The Forsyth Institute have found that blue light can be used to selectively suppress certain bacteria commonly associated with destructive gum disease.
Individuals have a right to participate in risky research trials, which might harm their health or even kill them, and institutional review boards (known as research ethics committees in the UK) – which are responsible for deciding whether a particular research trial can take place in a given institution – are potentially impeding the progress of research by rejecting such studies on ethical grounds, according to a Viewpoint published in The Lancet today [Wednesday 18 September].
Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
A non-invasive fingertip test can identify coronary disease at its earliest stages and may provide an easy to use tool for daily clinical practice, according to a recent study published in the Journal of the American College of Cardiology.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ricardo Cruzado, Po Box 7273, Caguas, PR 00726-7273 Ph: () - | Ricardo Cruzado, Ave. Luis Munos Marin, Caguas, PR 00725 Ph: (787) 653-3434 |
News Archive
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
Scientists at The Forsyth Institute have found that blue light can be used to selectively suppress certain bacteria commonly associated with destructive gum disease.
Individuals have a right to participate in risky research trials, which might harm their health or even kill them, and institutional review boards (known as research ethics committees in the UK) – which are responsible for deciding whether a particular research trial can take place in a given institution – are potentially impeding the progress of research by rejecting such studies on ethical grounds, according to a Viewpoint published in The Lancet today [Wednesday 18 September].
Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
A non-invasive fingertip test can identify coronary disease at its earliest stages and may provide an easy to use tool for daily clinical practice, according to a recent study published in the Journal of the American College of Cardiology.
› Verified 1 days ago
Dr. Daniel Mendez, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 Ave Luis Munoz Marin, Caguas, PR 00725 Phone: 787-653-3434 | |
Patricia Delgado, MD Radiology Medicare: Medicare Enrolled Practice Location: 100 Ave Luis Munoz Marin, Caguas, PR 00725 Phone: 787-653-3434 | |
Dr. Roberto L Gonzalez-sala, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 50 Ave L Munoz Marin, Quadrangle Medical Center, Suite 208, Caguas, PR 00725 Phone: 787-746-1688 Fax: 787-746-2292 | |
Dr. Amarilys Maldonado, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: Ave Luis Munoz Marin, Suite 202, Caguas, PR 00725 Phone: 787-746-1688 | |
Josue Vazquez Delgado, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 Ave Luis Munoz Marin, Caguas, PR 00725 Phone: 787-430-1208 | |
Dr. Jesus Daniel Buonomo, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Carr 1 Km 33.3 Ralph's Food Warehouse Local # 3, Viro, Caguas, PR 00725 Phone: 787-620-2100 Fax: 787-421-7171 | |
Dr. Jesus Daniel Velez Velez, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 Ave Luis Munoz Marin, Hospital Hima San Pablo Caguas, Caguas, PR 00725 Phone: 787-653-3434 Fax: 787-961-1901 |